Citius Oncology Inc
NASDAQ:CTOR
Intrinsic Value
The intrinsic value of one CTOR stock under the Base Case scenario is 6.6 USD. Compared to the current market price of 1.99 USD, Citius Oncology Inc is Undervalued by 70%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Citius Oncology Inc
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Citius Oncology Inc
Balance Sheet Decomposition
Citius Oncology Inc
Current Assets | 18.3m |
Other Current Assets | 18.3m |
Non-Current Assets | 73.4m |
Intangibles | 73.4m |
Free Cash Flow Analysis
Citius Oncology Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Citius Oncology Inc
Revenue
|
0
USD
|
Operating Expenses
|
-38.8m
USD
|
Operating Income
|
-38.8m
USD
|
Other Expenses
|
-3m
USD
|
Net Income
|
-41.8m
USD
|
CTOR Profitability Score
Profitability Due Diligence
Citius Oncology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Citius Oncology Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CTOR Solvency Score
Solvency Due Diligence
Citius Oncology Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Citius Oncology Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTOR Price Targets Summary
Citius Oncology Inc
According to Wall Street analysts, the average 1-year price target for CTOR is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.
Dividends
Current shareholder yield for CTOR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one CTOR stock under the Base Case scenario is 6.6 USD.
Compared to the current market price of 1.99 USD, Citius Oncology Inc is Undervalued by 70%.